Lung Cancer News
Week Ending September 20, 2021

Immunotherapy Offers Certain Patients With Small Cell Lung Cancer A ‘Ray of Hope’, Expert Says
“Recent developments in immunotherapy treatment have given patients with extensive-stage small cell lung cancer something to have faith in, according to an expert from City of Hope.”

A study from Italy suggests that patients diagnosed with lung cancer after the start of the “COVID-19 pandemic received treatment more quickly than did patients who were diagnosed with lung cancer in 2019.Study Reveals Shorter Time to Lung Cancer Treatment During COVID-19 Pandemic”
Trastuzumab Deruxtecan Yields Robust Antitumor Responses in HER2+ NSCLC
“Patients with HER2-mutated non–small cell lung cancer derived robust and long-lasting responses from fam-trastuzumab deruxtecan-nxki.”

Imfinzi plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
“LONDON, UK I September 18, 2021 I Updated results from the CASPIAN Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit at three years for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.”

Yale Cancer Center Study Shows New Drug Combinations Improve Outcomes for Patients with Advanced Lung Cancer
“New findings from a large study led by researchers at Yale Cancer Center shows the addition of the drugs oleclumab or monalizumab to durvalumab improved progression-free survival for patients with locally advanced non-small cell lung cancer (NSCLC). The data is part of the COAST trial and will be presented on September 17, 2021 at the annual meeting of the European Society for Medical Oncology (ESMO).”

ALK+ Non-Small Cell Lung Cancer
“Final results from a phase 3 trial showed that brigatinib continued to improve progression-free survival (PFS) compared with crizotinib in patients with advanced, ALK-positive non-small cell lung cancer (NSCLC)”

Takeda wins FDA approval for targeted lung cancer drug
“Japanese drugmaker Takeda said Wednesday it’s received Food and Drug Administration approval for the first oral therapy targeting a specific gene mutation in non-small cell lung cancer patients.”